A5077135127- Cancer Research and Treatments
- Virus-based gene therapy research
- Cancer Cells and Metastasis
- Mitochondrial Function and Pathology
- Immune cells in cancer
- Monoclonal and Polyclonal Antibodies Research
- 3D Printing in Biomedical Research
- Advanced Breast Cancer Therapies
- Lymphoma Diagnosis and Treatment
- Cancer-related Molecular Pathways
- Cancer Genomics and Diagnostics
- Click Chemistry and Applications
- Veterinary Oncology Research
- Histone Deacetylase Inhibitors Research
- Glioma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Protein Degradation and Inhibitors
- Cell Image Analysis Techniques
- Epigenetics and DNA Methylation
- Chronic Lymphocytic Leukemia Research
- Neuroblastoma Research and Treatments
University of Utah
2021-2023
Presage Biosciences (United States)
2014-2017
Recent studies reveal that lateral mitochondrial transfer, the movement of mitochondria from one cell to another, can affect cellular and tissue homeostasis. Most what we know about transfer stems bulk have led paradigm functional transferred restore bioenergetics revitalize functions recipient cells with damaged or non-functional networks. However, show also occurs between functioning endogenous networks, but mechanisms underlying how promote such sustained behavioral reprogramming remain...
Simultaneous in vivo assessment of multiple cancer drugs and drug combinations using microinjection technology predicts systemic response model tumors has shown feasibility for efficacy a pilot study patients.
Aberrant regulation of BCL-2 family members enables evasion apoptosis and tumor resistance to chemotherapy. functionally redundant counterpart, MCL-1, are frequently over-expressed in high-risk diffuse large B-cell lymphoma (DLBCL). While clinical inhibition has been achieved with the BH3 mimetic venetoclax, anti-tumor efficacy is limited by compensatory induction MCL-1. Voruciclib, an orally bioavailable stage CDK-selective inhibitor, potently blocks CDK9, transcriptional regulator Here, we...
While advances in high-throughput screening have resulted increased ability to identify synergistic anti-cancer drug combinations, validation of synergy the vivo setting and prioritization combinations for clinical development remain low-throughput resource intensive. Furthermore, there is currently no viable method prospectively assessing directly human patients order potentially tailor therapies. To address these issues we employed previously described CIVO platform developed a...
Abstract Spontaneously occurring soft tissue sarcoma ( STS ) is relatively common in canine cancer patients. Because of the similarities to human disease, s are a valuable and readily available resource for study new therapeutics. In this study, patient‐derived xenograft PDX model, CDX‐STS2 , was established. The model engrafted expanded systemic administration studies with chemotherapeutic agents commonly used treat including doxorubicin, docetaxel gemcitabine. Immunohistochemistry...
Abstract Triple negative breast cancer (TNBC) is a highly heterogeneous disease, notoriously challenging to treat with standard chemotherapy options, and therefore an area of intense focus for discovery novel effective combination therapies. Here we used previously described technology platform called CIVO, which enables assessment multiple drugs drug combinations simultaneously in living tumors, identify that result synergistic anti-tumor activity the HCC1187 model TNBC. Our study focused...
Abstract Lateral transfer of mitochondria occurs in many physiological and pathological conditions. Given that provide essential energy for cellular activities, mitochondrial is currently thought to promote the rescue damaged cells. We report between macrophages breast cancer cells, leading increased cell proliferation. Unexpectedly, transferred macrophage are dysfunctional, lacking membrane potential. Rather than performing accumulate reactive oxygen species which activates ERK signaling,...
Abstract Proper selection of anti-cancer agents at the earliest stage patient treatment following diagnosis disease relapse is expected to substantially impact clinical response treatment. Currently, genomic approaches personalized cancer treatments have been yielded mixed results, while empirical tests assess tumor responsiveness limited ex vivo systems that disrupt native microenvironment and show predictive value. To address need for multiplexed in chemosensitivity testing, we developed a...
Abstract Assessment of anti-cancer drug efficacy is an imprecise and challenging undertaking. Early candidate selection typically based on results from systemically treated animal models later by performance in human trials where patients are exposed to often toxic levels drug, prior obtaining readouts tumor response. In both these testing models, only one can be tested at a time. Using methods, over 90% new oncology drugs fail provide benefit for clinical trials. To improve the predictive...
Abstract We report the initial clinical findings of a device platform to test multiple therapeutic options simultaneously in individual living tumors within patient population, detailing for first time comparative effects different drugs intact tumors. Most early cancer drug discovery is performed under vitro conditions cell-based models that poorly represent disease they are intended and have poor track record predicting success subsequent trials. To enable vivo analysis anti-cancer agent...
e22177 Background: Cancer drug developers face a fundamental challenge in the way new candidate drugs are evaluated. Early stage compounds tested preclinical models that lack important components of complex tumor microenvironment and poorly reflect disease seen clinic. To address this issue we present technology called CIVO demonstrates potential for testing experimental directly tumors cancer patients prior to entry into formal clinical trials. Methods: A two-stage feasibility study was...